Outlook Therapeutics (OTLK) said Friday it has regained compliance with Nasdaq's minimum bid price listing requirement.
The company said it was notified that it had regained compliance as the closing bid price of its shares had been at $1 per share or greater for 10 consecutive business days.
Shares of Outlook Therapeutics were 3.5% lower in Monday trading.